Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1Leukemia, B-Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1Blood Protein Disorders 1

Interventions

aldesleukin 9Interleukin-2 9Nivolumab 7fludarabine phosphate 6Dacarbazine 6Cyclophosphamide 6fludarabine 5Temozolomide 4Ipilimumab 4Fluorouracil 4montanide ISA 51 3Surveys and Questionnaires 3Semaxinib 3Radiotherapy 3Radiation 3Mohs Surgery 3Educational Status 3Cisplatin 3Allovectin-7 3zanolimumab 2talabostat 2sonidegib 2poly ICLC 2binimetinib 2Whole-Body Irradiation 2Vinblastine 2Vemurafenib 2Tacrolimus 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Skin Neoplasms × Hsp90 inhibitor KU757 × Clear all
NCT01657591 2023-01-19

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
21 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡